Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›FOSAMAX Once Weekly 70 mg tablets
Medicines register · Ireland

FOSAMAX Once Weekly 70 mg tablets

Authorisation PA23198/003/001 · Organon Pharma (Ireland) Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Organon Pharma (Ireland) Limited (all products →)
Active substance
Alendronic acid
Dosage form
Tablet
Route of administration
Oral use
ATC codes
M05BA, M05BA04
First authorised
17/05/2001
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Alendronic acid: supply and approvals

13 authorised products on the HPRA list contain Alendronic acid. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 25 years (since 17 May 2001). The HPRA list marks it as marketed in Ireland.

Other medicines with Alendronic acid in Ireland

12 other products on the HPRA list contain Alendronic acid, from 5 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Alendronate/Colecalciferol Teva 70 mg/2800 IU tabletsTeva Pharma B.V.National authorisation (PA)Marketed
Alendronate/Colecalciferol Teva 70 mg/5600 IU tabletsTeva Pharma B.V.National authorisation (PA)Marketed
Binosto Once Weekly 70 mg effervescent tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Fostepor Once Weekly 70mg tabletsViatris LimitedNational authorisation (PA)Marketed
Osteomel Once Weekly 70 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Romax Once Weekly 70mg TabletsAurobindo Pharma (Malta) LimitedNational authorisation (PA)Marketed
Adrovance 70 mg/2800 IU tabletsN.V. OrganonCentralised EU authorisationNot stated
Adrovance 70 mg/5600 IU tabletsN.V. OrganonCentralised EU authorisationNot stated
Fosavance 70 mg/2800 IU tabletsN.V. OrganonCentralised EU authorisationNot stated
Fosavance 70 mg/5600 IU tabletsN.V. OrganonCentralised EU authorisationNot stated
VANTAVO 70 mg/2800 IU tabletsN.V. OrganonCentralised EU authorisationNot stated
VANTAVO 70 mg/5600 IU tabletsN.V. OrganonCentralised EU authorisationNot stated

Other substances in ATC group M05BA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 11 other active substances share the group M05BA with this product:

Ibandronic acid (12) · Zoledronic acid monohydrate (8) · Zoledronic acid (6) · Ibandronate sodium monohydrate (5) · Risedronate sodium (3) · Sodium alendronate (1) · Alendronate sodium trihydrate (1) · Ibandronic acid monosodium monohydrate (1) · Ibandronate sodium (1) · Risedronate sodium hemipentahydrate (1) · Alendronate sodium monohydrate (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Organon Pharma (Ireland) Limited holds 55 products on the HPRA list, with 22 different active substances; 42 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.